ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection

Also written as “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection”, “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w” and “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w”.

Its studies are mostly in Multi-centric Castleman's Disease · Arthritis, Rheumatoid, led by Beijing VDJBio.

Furthest: phase 3, since Dec 5, 20243 company-led studies, 3 open or runningNext primary completion: Jun 9, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing VDJBio33 open or runningphase 3since Dec 5, 2024Apr 19, 2022Jun 9, 2027phase 3 · NCT07872423

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 19, 2022First study: phase 2 study in Idiopathic Multicentric Castleman's DiseaseFirst studyNCT05345522 · 25 enrolled · China
  2. Dec 5, 2024Phase 3 study in Arthritis, RheumatoidNCT06726096 · 615 planned · China
  3. Mar 19, 2026Phase 3 study in Multi-centric Castleman's DiseaseNCT07872423 · 45 planned · China

Ahead

  1. Jun 9, 2027Primary completion: phase 3 study in Multi-centric Castleman's DiseaseNCT07872423

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07872423Multi-centric Castleman's Disease · China3RecruitingJun 9, 202745
NCT06726096Arthritis, Rheumatoid · China3By invitationApr 20, 2026615
NCT05345522Idiopathic Multicentric Castleman's Disease · China2Active, not recruitingNov 27, 202225

How it is read

Names in the registry

  • “Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection”, 1 entry
  • “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection”, 1 entry
  • “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg, q2w”, 1 entry
  • “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6 mg/kg, q2w”, 1 entry
  • “Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8 mg/kg, q2w”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.